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Abstract
Background: The intent of this pooled analysis as part of the German society for radiation oncology (DEGRO)
stereotactic body radiotherapy (SBRT) initiative was to analyze the patterns of care of SBRT for liver oligometastases
and to derive factors influencing treated metastases control and overall survival in a large patient cohort.
Methods: From 17 German and Swiss centers, data on all patients treated for liver oligometastases with SBRT since
its introduction in 1997 has been collected and entered into a centralized database. In addition to patient and
tumor characteristics, data on immobilization, image guidance and motion management as well as dose
prescription and fractionation has been gathered. Besides dose response and survival statistics, time trends of the
aforementioned variables have been investigated.
Results: In total, 474 patients with 623 liver oligometastases (median 1 lesion/patient; range 1–4) have been
collected from 1997 until 2015. Predominant histologies were colorectal cancer (n = 213 pts.; 300 lesions) and breast
cancer (n = 57; 81 lesions). All centers employed an SBRT specific setup. Initially, stereotactic coordinates and CT
simulation were used for treatment set-up (55%), but eventually were replaced by CBCT guidance (28%) or more
recently robotic tracking (17%). High variance in fraction (fx) number (median 1 fx; range 1–13) and dose per
fraction (median: 18.5 Gy; range 3–37.5 Gy) was observed, although median BED remained consistently high after
an initial learning curve. Median follow-up time was 15 months; median overall survival after SBRT was 24 months.
One- and 2-year treated metastases control rate of treated lesions was 77% and 64%; if maximum isocenter
biological equivalent dose (BED) was greater than 150 Gy EQD2Gy, it increased to 83% and 70%, respectively.
Besides radiation dose colorectal and breast histology and motion management methods were associated with
improved treated metastases control.
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Conclusion: After an initial learning curve with regards to total cumulative doses, consistently high biologically
effective doses have been employed translating into high local tumor control at 1 and 2 years. The true impact of
histology and motion management method on treated metastases control deserve deeper analysis. Overall survival
is mainly influenced by histology and metastatic tumor burden.
Keywords: Stereotactic body radiotherapy, Liver oligometastases, Outcome, Treated metastases control,
Oligometastases, Oligo-recurrence, Sync-oligometastases
Background
Stereotactic body radiation therapy (SBRT) is a dedi-
cated form of external beam radiotherapy which is char-
acterized by a steep dose gradient outside the irradiated
tumor volume while escalating the dose inside the target
volume. Combined with high precision patient setup and
image guidance, this is a highly effective local treatment
while achieving a very low toxicity profile. Usually, treat-
ment protocols include higher single doses and the frac-
tion number ranges from a radiosurgery (1 fraction)
procedure up to 10 fractions.
Established for treating brain metastases, SBRT has
been expanded to treat tumors and metastases at nu-
merous body sites including the lung, liver, bone and
prostate. Most experience has been gathered so far for
the treatment of NSCLC stage I in inoperable patients
where it is now considered standard of care [1].
Very early, SBRT has been evaluated in patients with lung
and liver oligometastases as well, though published series
only report small patient numbers and different treatment
protocols. Recently, with the widespread adoption of the
concept of oligo-metastases [2], interest has been increased
and larger series have been published [3]. In addition, the
terms of oligo-recurrence (metastases detected while pri-
mary tumor controlled) and sync-oligometastases (primary
tumor and limited number of metastases detected simul-
taneously) have been coined to depict the occurrence of
metastases in the course of oligometastasic disease [4, 5].
In contrast to lung tumors where consistent rates of
treated metastases control above 85% have been re-
ported in recent studies, results with regard to treated
metastases control of liver lesions are more heteroge-
neous ranging from 60 to 100% and 55%–90% at 1 and
2 years, respectively [6–13]. Currently, SBRT is mainly
being used if a patient is not medically fit for surgery,
not technically resectable or declines surgical interven-
tion as well as if other local therapies like radiofrequency
ablation are not possible due to size or location near lar-
ger vessels, and is has been added to the possible armen-
tarium of local therapies to be considered besides
resection in metastasized CRC [14, 15]. Still, results of
liver SBRT are very encouraging especially considering
the larger size and the critical location of the lesions
compared to other local ablative therapies [8, 10, 16, 17].
Patient selection for treatment is a critical issue. Most
benefit regarding progression free survival and possibly
overall survival is expected in the state of oligo-
recurrence, as witnessed in small prospective series for
oligometastatic NSCLC [18, 19]. In addition, the recently
presented outcome data of the EORTC-NCRI CCSG-
ALM Intergroup 4004 trial could demonstrate in a ran-
domized fashion a positive effect of a local ablative ther-
apy in the form of radiofrequency ablation on OS in
patients with liver oligometastases from CRC in addition
to chemotherapy [20]. Currently, up to 4 metastases is
considered a safe and reasonable number to treat [7], al-
though most series reported a median number of metas-
tases treated of one. Patients should be in a reasonable
performance status (KPS ≥70) and the projected survival
should be beyond 6 months. The optimal treatment, in-
cluding the use of SBRT, should be ideally discussed and
recommended in a multidisciplinary tumor board [14].
Still, relevant questions remain open regarding optimal
patient selection, radiation dose and fractionation or
radio-sensibility of different histologies which cannot be
answered satisfactorily with the current available data
due to the small sample size of the prospective and
retrospective reports.
The intent of this pooled analysis is to set-up an
outcome-based database and analyse the pattern of care
of liver SBRT in Germany and Switzerland. We herein
report on the evolution of SBRT, treatment characteris-
tics as well as outcome with respect to treated metasta-
ses control and overall survival in 474 patients with 623
liver oligometastases.
Methods
Patient eligibility
All patients treated with SBRT for liver oligometastases
after its introduction into the clinic in Germany and
Switzerland between 1997 and June 2015 were eligible to
be included in this pattern of care analysis. Patient,
tumor and treatment characteristics were retrospectively
collected and entered in a centralized database. Centers
were eligible to provide patient data, if they were per-
forming liver SBRT. No formal inclusion criteria for par-
ticipation were mandatory.
Andratschke et al. BMC Cancer  (2018) 18:283 Page 2 of 11
Inclusion criteria were patients with liver oligometas-
tases from any histology-proven primary solid tumor.
Clinical diagnosis was based on radiological imaging with-
out mandatory biopsy of the liver metastasis. Patients re-
ceiving liver SBRT were included when they were
medically inoperable, presented with non-resectable me-
tastases which were not qualifying for alternative focal
treatment such as radiofrequency ablation (RFA) or if they
refused invasive therapies. SBRT definition was based on
the target volume concept, application of conformal treat-
ment planning and stereotactic or image-guided patient
setup as well as hypo-fractionated treatment application.
The participating centers used, based on available technol-
ogy and tumor size and location in correlation to organs-
at-risk, a center-specific fractionation schedule.
Patient data was reported anonymously and pooled in
a common database by the coordinating center (Depart-
ment of Radiation oncology, University Hospital of Zur-
ich, Zurich, Switzerland). The database consisted of
more than 50 parameters including patient characteris-
tics, primary tumor characteristics and oncological
course of disease and further therapies. Additionally,
technical data on radiotherapy delivery as well as clinical
outcome were collected and further analyzed.
The multicenter data collection, database and analysis
was approved by the Ethics committee of the Kanton
Zurich, Switzerland (BASEC-Nr. 2016–00744). The data
collection of the individual participating centers was ap-
proved according to local regulations and approved by
the respective local ethics committees.
Endpoints and toxicity definitions
Local failure of a metastatic lesion was defined as either
reappearance after complete remission or re-growth
after initial partial response to SBRT in follow-up CT or
MRI scans. PET-CT scans were used by some centers in
equivocal cases to confirm local recurrence. Extrahepatic
tumor status was classified as either no evidence of dis-
ease (NED), stable (SD) or progressive disease (PD).
Acute toxicity was scored according to the National
Cancer Institute CTCAE v3.0 criteria during and up to
3 months after SBRT. Late toxicity was graded using the
RTOG/EORTC criteria.
Statistical analysis
Actuarial survival time and freedom from local failure
(called “treated metastases control”) were calculated ac-
cording to the Kaplan-Meier method. For univariate and
multivariable analysis of prognostic factors (listed in
Table 3) the Cox proportional hazard model was used.
Comparison of survival between groups was performed
using the log-rank test.
For overall survival, any death and for disease specific
survival death from the underlying cancer was defined
as an event. For actuarial local tumor control, progres-
sion of the treated lesion was defined as stated in the
methods section. For this endpoint, patients who died
from other diseases without tumor regrowth or progres-
sion at that time were censored. All time intervals were
calculated from the last day of SBRT.
Biological effective doses were calculated according to
the LQ formalism:
BED ¼ n  d  dα
β
 !
with n being the number of fractions, d the daily single
fraction dose and using an alpha-beta for tumor tissue of
10 Gy.
BEDisocenter of 150 Gy10 has been determined as
descriminator for treated metastases control in a separ-
ate ROC analyis (data not shown) and is in line with a
previous report from our group [21].
PTV volumes have been used as surrogates for the
GTV volumes in the multivariable Cox regression
model. This was based on the approach that the results
of the multivariable Cox proportional hazard model after
imputation of missing GTV values using the R package
“mice” were comparable with the respective results after
inclusion of PTV instead of GTV (data not shown). As
the same variables had been chosen by the model on the
respective endpoints, PTV was chosen for use in multi-
variable cox regression analysis instead of GTV to work
with real data, instead of imputed one. Statistical analysis
was performed with the R statistical environment ver-
sion 3.3.1.
Results
Patient and tumor characteristics
In total, 17 German and Swiss academic and non-
academic centers participated and collected data on 474
patients with a total of 623 metastases. Patient data was
collected from university (n = 13), public (n = 2) and pri-
vate centers (n = 2) in Germany and Switzerland includ-
ing overall data from 474 patients with 623 liver
oligometastases treated with SBRT. The most frequent
primary tumor was colorectal cancer (48.1%), followed
by breast cancer (13.3%), non-small cell lung cancer
(6.1%) and pancreatic cancer (5.1%). In most patients,
one liver metastasis was treated (n = 369). In the remain-
der cohort two to four metastases (n = 2: 75 pts.; n = 3,
15 pts.; n = 4: 9 pts) have been treated simultaneously.
Repeat stereotactic radiotherapy for new liver oligome-
tastases was performed in only 4 patients. Median
follow-up was 15 months (range: 1–178 months). SBRT
treatment of the liver metastasis was performed at a me-
dian time of 27 months (range: 0–392 months) after
diagnosis of the primary tumor.
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The median number of patients per institution was 13
(range: 2–178), the median number per institution per
year was 5 (range: 1–13). Patient and treatment charac-
teristics are summarized in detail in Tables 1 and 2.
Patterns of care
SBRT for liver oligometastases was first introduced in
1997 and adopted for clinical evaluation by three univer-
sity centers between 1997 and 2000. All three centers
used a vigorous patient immobilization for setup and a
stereotactic frame for target localization. General adop-
tion of SBRT for liver oligometastases developed slowly
and broader introduction into clinical routine started in
2008 (see Fig. 1a).
Time trends in dose prescription
Despite careful introduction into clinical routine, no
standardized dose and fractionation protocol has
emerged over time. On the contrary, significant interin-
stitutional variation in the single fraction, total dose
prescribed, number of fractions and the respective pre-
scription isodose could be observed (Fig. 1b).
There was as significant time-trend in total dose pre-
scribed in the initial phase after introduction of SBRT.
The mean BEDisocenter before 2003 was 102.5 Gy,
whereas it significantly rose to 134.3 Gy thereafter and
remained constant (p < 0.001; Fig. 1b).
Treated metastases control
Treated metastases control in the total cohort with 607
evaluable metastases was 76.1%,63.8% and 55.7% at 1,2
and 3 years (Fig. 3a). In univariate analysis, maximum
BED, histology, systemic therapy before SBRT, GTV and
PTV volume were all significant predictors for treated
metastases control (Fig. 3b-d; Table 3). Patients receiving
systemic therapy before SBRT had a worse treated me-
tastases control rate compared to patient who had re-
ceived no pretreatment therapy. Metastases from
colorectal cancer had a significantly worse treated me-
tastases control rate at one year (67%) compared to
breast cancer (91%), NSCLC (88%) or other histologies
Table 1 Patient Characteristics
No. of Patients/ Metastases Perent Median Minimum Maximum
474 pts.
Age (yr) 64 15 93
Sex
male 268 pts. 56.7%
female 206 pts. 43.3%
Pretreatment performance scale (Karnofsky index) (%) 90 40 100
Histology
Colorectal cancer 228 pts. 48.1%
Breast cancer 63 pts. 13.3%
NSCLC 29 pts. 6.1%
Pancreatic cancer 24 pts. 5.1%
Others 130 pts. 27.4%
Chemotherapy prior to SBRT
Yes 325 pts. 65.6%
No 80 pts. 16.9%
Unknown 68 pts. 17.6%
Number of liver metastases per patient 474 pts. / 623 mets 1 1 4
n = 1 372 pts. 78.5%
n = 2–4 102 pts. 21.5%
Status of extrahepatic disease
Oligo-recurrence group 119 pts. 25.1%
Sync-oligometastases group 235 pts. 49.6%
Unknown 120 pts. 25.3%
Time interval between primary tumor diagnosis
and SBRT treatment (months)
27.0 0.0 391.0
Follow-up (months) 15 1 178
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(80%). Patients treated after 2003 had a significant better
treated metastases control rate compared to patients
treated before. Local control for metastases treated with
advanced motion management methods defined as ei-
ther gating (active breathing control; free breathing gat-
ing) or tracking (fiducial based) was significantly higher
compared to methods relying on target localization dur-
ing free breathing, including CBCT based strategies.
As sufficient events were available, all variables investi-
gated in univariate analysis were entered in the multivar-
iable proportional hazard cox regression model. As a
considerable proportion of GTV volumes (49%) were
missing, PTV volumes have been entered in multivariate
analysis instead. Systemic therapy before SBRT, PTV vol-
ume, BEDisocenter, motion management methood, and
SBRT treatment before 2003 remained as independently
significant variables.
Overall survival
Overall survival in the total cohort was 70%, 29% and
15% at one, 3 and 5 years (Fig. 2a). Seven patients expe-
rienced a long-term survival and could be observed at
Table 2 SBRT Treatment Characteristics
No. of Lesions Percent Median Minimum Maximum
623
GTV volume (ccm) 27 0.6 699
PTV volume (ccm) 71.3 4.5 1074.0
Single fraction dose (PTV encompassing) in Gy 12 2.1 30.0
Single fraction dose (isocenter) in Gy 18.48 2.95 46.9
Total BED (PTV encompassing) in Gy 69.4 10.4 187.5
Total BED (Isocenter) in Gy 125.9 27.2 292.4
Prescription isodose (%) 80.0 42.0 100.0
Most common prescription isodoses
95% isodose 70 11.2%
80% isodose 199 31.9%
65% isodose 131 21.0%
60% isodose 38 6.0%
Number of SBRT fractions 3 1 13
1-fraction SBRT 189 30.3
3-fraction SBRT 207 33.2
5-fraction-SBRT 158 25.4
other fractionation schemes 69 11.1
GTV gross target volume, PTV planning target volume, BED biological effective dose
Fig. 1 a Cumulative number of centers practicing liver SBRT and number of treated lesions from 1997 to 2014. b Change of prescribed
biologically effective dose (BED) for SBRT liver oligometastases from 1997 to 2014
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10 years of follow-up. In univariate Cox regression ana-
lysis, KPS, histology (breast and colorectal cancer having
a better prognosis) and GTV volume were all significant
predictors for overall survival (Table 3). Interestingly,
pre-SBRT chemotherapy, number of metastases treated
and extrahepatic disease status were not associated with
overall survival.
Also, achieving treated metastases control did not in-
fluence overall survival in univariate analysis. In con-
trast, early local recurrence (within 6 months of SBRT)
versus late local recurrence was significantly associated
with worse survival (Table 3; Fig. 2b).
In multivariable cox regression, only tumor volume,
histology (specifically colorectal histology) and early vs.
delayed local recurrence remained independent predic-
tors of overall survival.
Toxicity
Acute toxicity data was available for 73% of the patients
(n = 347). Grade 1–2 toxicity was observed in 23% and
consisted mostly of fatigue, nausea and diarrhea. Grade
3 acute toxicity occurred in less than 1% with one gastric
ulcer being the most severe side effect. No toxicity
greater grade 3 was observed.
Chronic toxicity data was available for 44% of the pa-
tients (n = 208) and consisted of fatigue, nausea, diar-
rhea, liver enzyme elevation and jaundice. Chronic grade
1–2 was observed in 10% and chronic grade 3 toxicity in
1.4% with no chronic toxicity greater than grade 3 re-
ported. Grade 3 toxicity was due to radiation hepatitis
with enzyme elevation (n = 1), liver fibrosis (n = 3; one
with consecutive varicosis and bleeding) and necrotic re-
action of treated metastases (n = 1).
Table 3 Univariate and multivariate analysis for local control and overall survival according to patient and tumor characteristics
Univariate Multivariate
HR (CI) p-value HR (CI) p-value
Local control
Prior CTxa 2.19 (1.23–3.91) 0.008 2.19 (1.18–4.06) 0.13
Histology (CRC) 1.99 (1.31–3.04) 0.001 1.71 (1.04–2.80) 0.03
Histology (BCa) 0.53 (0.25–1.13) 0.10 0.45 (0.19–1.02) 0.06
Histology (NSCLC) 0.86 (0.26–2.85) 0.81 0.67 (0.19–2.35) 0.54
GTV Volumec 1.004 (1.002–1.005) < 0.001 –
PTV Volumec 1.002 (1.001–1.003) < 0.001 1.001 (1.00–1.002) 0.003
BED Isocenterc 0.993 (0.989–0.997) < 0.001 0.99 (0.98–1.00) 0.002
BED prescriptionc 0.72 (0.51–1.01) 0.003 1.00 (0.99–1.01) 0.970
Advanced Motion managementa 0.46 (0.29–0.72) < 0.001 0.57 (0.33–0.96) 0.04
Before 2003a 1.50 (1.04–2.16) 0.031 1.02 (0.61–1.70) 0.932
Overall survival
KIc 0.69 (0.51–0.94) 0.02 0.74 (0.53–0.98) 0.06
Gender 0.80 (0.63–1.01) 0.06 0.76 (0.54–1.06) 0.10
Histology (CRC) 0.61 (0.46–0.79) < 0.001 0.64 (0.45–0.92) 0.01
Histology (BCa) 0.52 (0.36–0.76) < 0.001 0.60 (0.36–0.99) 0.05
Histology (NSCLC) 1.42 (0.87–2.33) 0.16 1.14 (0.64–2.07) 0.65
Prior CTxa 0.91 (0.65–1.27) 0.58 1.17 (0.76–1.80) 0.47
Extrahepatic statusb 0.81 (0.60–1.1) 0.18 0.83 (0.49–1.43) 0.52
Solitarya 0.73 (0.57–0.92) 0.007 1.12 (0.61–2.03) 0.72
# of liver metastases (1 vs. 2–4) 0.94 (0.72–1.23) 0.65 0.80 (0.52–1.23) 0.32
GTV Volumec 1.003 (1.002–1.004) < 0.001 –
PTV Volumec 1.002 (1.001–1.002) < 0.001 1.002 (1.001–1.003) < 0.001
Local recurrence after SBRTa 0.88 (0.68–1.51) 0.36 0.82 (0.56–1.19) 0.29
BED isocenterc 0.997 (0.994–1.00) 0.06 1.00 (0.99–1.004) 0.97
CTx chemotherapy, BCa breast cancer, BED biologically effective dose, GTV gross tumor volume, PTV planning target volume, PS performance status, HR hazard
ratio, CI 95% confidence interval), CRC corolrectal caner, NSCLC non-small cell lung cancer
abinary coded variables with yes vs. no; bcomplete remission/stable disease vs progressive disease; cvolume and minimum biologically effective dose as
continuous variables
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Discussion
In this mutli-center database centralized data on patient,
tumor and treatment characteristics of a large body of pa-
tients treated with SBRT for liver oligometastases to de-
scribe the evolution and patterns of care of liver SBRT
between 1997 and 2015 in Germany and Switzerland has
been collected. In addition, outcome data including fac-
tors predicting for treated metastases control and overall
survival as well as toxicity could be successfully gathered:
for treated metastases control, systemic therapy before
SBRT, PTV volume, BEDisocenter, motion management
methood, could be identified as independently significant
variables; for overall survival, PTV volume, histology
(colorectal histology exhibiting a better prognosis) and
early vs. delayed local recurrence were independent pre-
dictors of overall survival.
Implementation of liver SBRT started in 1997 with
CT-simulated frame-based stereotactic approach. With
the advent of 4D CT and CBCT based image-guidance
in addition to reports on safety and efficacy of liver
SBRT, a steady and continued adoption of this technol-
ogy started in 2005 (Fig. 1a). Over time, more advanced
motion management methods were introduced, mainly
implemented with robotic tracking systems, and − al-
though scarcely − other motion mitigation approaches
like active breathing control or gating.
Although SBRT had been introduced at a high-quality
level across all centers, the applied fractionation scheme
greatly varied with regards to fractionation and total
dose (Table 2). Nevertheless, the applied mean BEDisocen-
ter was consistently high and reflects the general notion
of the initial dose finding learning curve (Fig. 1b). In
these first years, a consistent shift to higher prescription
doses was observed around 2003 (Fig. 1b) which trans-
lated in a noticeable improvement in treated metastases
control. This indicates that centers starting SBRT for
liver oligometastases after 2003 did not include a strat-
egy of dose escalation to gain experience, but adopted -
if possible in the individual patient situation - an effect-
ive BED at the time of individual clinical introduction of
SBRT. Inhomogeneous dose prescription - i.e. lower pre-
scription doses at the PTV periphery allowing signifi-
cantly higher doses to build up towards the iso-center –
were applied with the 80%- and 65%- isodoses being the
most common prescription isodoses.
Unfortunately, most of the previously published stud-
ies only report the PTV prescription dose and no details
on the dose distribution within the PTV or GTV, so that
a direct comparison of the different doses applied is dif-
ficult [8, 10, 11, 22–26]. Therefore, despite a consistent
dose response relationship reported in most of these
publications, a clear conclusion on the minimally re-
quired PTV prescription dose or the relevance of in-
homogeneous dose distribution within the PTV to
achieve a certain level of treated metastases control is
difficult.
A clear dose response relationship could be established
within our dataset over all histologies for the PTV pre-
scription dose as well as the dose at the isocenter recal-
culated to the BED using the LQ-formalism. Finally,
BEDisocenter remained the strongest factor influencing
treated metastases control in MVA. Consistent with our
dose-response analysis in primary and secondary lung
tumors [21], we believe that the dose distribution and
the BED within the GTV is clinically more relevant than
the minimally PTV prescribed dose and BEDisocenter
Fig. 2 Kaplan-Meier estimated overall survival a) for the whole patient cohort and b) stratified for patients with local recurrence within 6 months
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serves as the most robust GTV dose surrogate in this re-
spect. In our liver SBRT cohort, If a BEDisocenter of
greater than 150 Gy10 was applied (Fig. 3d), a treated
metastases control of > 80% at 2 years could be achieved
which is comparable to the published literature [21].
As reported by other groups, tumor volume (GTV)
and planning target volume (PTV) were predictive of
local failure as well [27, 28], though this has not been
found in other reports [10, 11]. Most interestingly, pre-
SBRT chemotherapy and colorectal histology appeared
as negative predictive factors for treated metastases con-
trol. This has been separately addressed by our group
where we could show that the negative influence of pre-
SBRT chemotherapy on treated metastases control was
the major confounding factor of the inferior treated me-
tastases control in colorectal histology [16]. In contrast,
breast cancer histology appears to be more responsive to
SBRT irrespective of the pre-SBRT chemotherapy status.
Due to the small numbers of patients with breast cancer
in our cohort, this finding was only borderline signifi-
cant in multivariable analysis (Table 3).
Considering the general negative selection of patients
which were not considered as surgical candidates, overall
survival appears to be reasonable and indicates that lon-
ger term survival beyond 5 years is possible after SBRT.
In multivariable only histology, tumor volume and early
vs. delayed local recurrence remained independent predic-
tors of overall survival. Interestingly, pre-treatment
chemotherapy did not influence overall survival in our co-
hort. This is in contrast to the recent update of the
EORTC 40004 trial where the addition of RFA to systemic
therapy improved overall survival and the report by Fode
et al. on SBRT for oligo-metastatic solid cancer where pre-
SBRT chemotherapy was associated with improved
survival as well. Most probably, patient selection is the
dominating factor for these contrary findings and reflects
the difficulties in comparing different series for oligo-
metastatic solid tumors: in our series, 75% of patients had
a singular liver oligometastases in contrast to 15% [20]
and 50% [29].
The finding is the most intriguing finding: patients de-
veloping local recurrence within 6 months compared to
later time points had a significant worse overall survival.
As developing a local recurrence per se (not taking a
time factor into account) had no impact on overall sur-
vival, this finding is most probably a reflection of a more
aggressive tumor phenotype in these patients and can
not necessarily be attributed to the effect of treated me-
tastases control (in the liver) on overall survival. There-
fore, it would be desirable to be able to predict the
projected individual OS to define which patient would
benefit most from local therapies such as SBRT. Further
analysis of the dataset will focus on developing predict-
ive models to estimate individual patient’s survival.
Reported toxicity profile for acute and late toxicity was
very favorable. Documentation for acute toxicity was
very good with 73% and dropped considerable for late
toxicity with 44%. We are aware that due to the retro-
spective nature of the reporting, especially late toxicity
scoring must be viewed with caution. Still, no reported
grade 4 or 5 toxicity within the follow-up period and a
grade 3 rate of less than 2 % seems to be very encour-
aging and reflects the careful introduction of SBRT with
reasonable fractionation schemes for abdominal SBRT.
Conclusions
After an initial learning curve with regards to total cu-
mulative doses, consistently high biologically effective
Fig. 3 Kaplan-Meier estimated treated metastases control for all patients (a) and stratified by (b) pre-SBRT chemotherapy, (c) histology,
(d) BEDisocenter
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doses have been employed translating into high local
tumor control at 1 and 2 years. Through the continuous
technical development, the implementation of advanced
motion management techniques such as gating with ac-
tive breathing control, tracking and use of fiducial
markers have increased during the last years and con-
tributed to the improvement in treated metastases con-
trol over time while minimizing the excellent therapy-
related toxicity profile. Besides radiation dose, tumor
volume, pre-SBRT chemotherapy and histology have
been identified as predictive factors for treated metasta-
ses control. OS is mainly governed by histology and
tumor volume. Most intriguingly, local recurrence per se
did not influence prognosis, but the time-dependent oc-
currence: patients with early recurrence within 6 months
had a significantly worse OS.
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